We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+4.97%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$484M
AUM Growth
+$61.6M
Cap. Flow
+$48.7M
Cap. Flow %
10.05%
Top 10 Hldgs %
47.59%
Holding
66
New
18
Increased
20
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.8M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$13.7M
4
FTD
FTD Companies, Inc. Common Stock
FTD
+$11.4M
5
VSTO
Vista Outdoor Inc.
VSTO
+$11.1M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$12.9M
2
LVS icon
Las Vegas Sands
LVS
+$12.6M
3
CPB icon
Campbell Soup
CPB
+$9.55M
4
WFM
Whole Foods Market Inc
WFM
+$9.39M
5
URBN icon
Urban Outfitters
URBN
+$8.54M

Sector Composition

Rank Sector Weight
1 Healthcare 37.37%
2 Consumer Discretionary 21.51%
3 Consumer Staples 10.76%
4 Industrials 3.99%
5 Financials 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LVS icon
51
Las Vegas Sands
LVS
$32B
– –
-236,000
Closed -$12.6M
OCGN icon
52
Ocugen
OCGN
$420M
– –
-21,067
Closed -$2.11M
PCRX icon
53
Pacira BioSciences
PCRX
$1.05B
– –
-400,000
Closed -$12.9M
SIG icon
54
Signet Jewelers
SIG
$3.81B
– –
-62,000
Closed -$5.84M
TSCO icon
55
Tractor Supply
TSCO
$16.5B
– –
-500,000
Closed -$7.58M
URBN icon
56
Urban Outfitters
URBN
$6.44B
– –
-300,000
Closed -$8.54M
ACOR
57
DELISTED
Acorda Therapeutics
ACOR
– –
-3,567
Closed -$8.05M
ZSAN
58
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-1,714
Closed -$936K
DNKN
59
CALL
DELISTED
Dunkin' Brands Group, Inc.
DNKN
– –
-60,000
Closed -$3.15M
JCP
60
DELISTED
J.C. Penney Company, Inc.
JCP
– –
-700,000
Closed -$5.82M
BLPH
61
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-66,667
Closed -$520K
PAY
62
CALL
DELISTED
Verifone Systems Inc
PAY
– –
-700,000
Closed -$12.4M
WFM
63
DELISTED
Whole Foods Market Inc
WFM
– –
-312,000
Closed -$9.39M
ROKA
64
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
– –
-236,000
Closed -$1M
SHPG
65
DELISTED
Shire pic
SHPG
– –
-46,000
Closed -$7.84M
1 2
3

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Armistice Capital held 66 positions worth $484M, up 15% from $423M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital deployed $48.7M of net new capital in Q1 2017, opening 18 new positions and adding to 20 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 40,000 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 36% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was Aralez Pharmaceuticals Inc., an estimated $8.03M trimmed.

  • Armistice Capital's largest Q1 2017 buy was Regeneron Pharmaceuticals: 40,000 shares worth $15.5M.
  • Armistice Capital added most to Vanda Pharmaceuticals in Q1 2017, an estimated $14.7M increase.
  • Armistice Capital's biggest Q1 2017 reduction was Aralez Pharmaceuticals Inc., cutting an estimated $8.03M.
  • Armistice Capital fully exited Pacira BioSciences in Q1 2017, selling an estimated $12.9M.
  • Armistice Capital's ten largest holdings make up 48% of its $484M portfolio in Q1 2017.
  • Armistice Capital opened 18 new positions and closed 19 in Q1 2017.
  • Armistice Capital's portfolio value rose 15% quarter-over-quarter to $484M.

Based on Armistice Capital's 13F filing for Q1 2017, filed 15 May 2017.